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Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) have increased cardiovascular risk.
Natriuretic peptides (NP) in other populations are useful in identifying cardiovascular disease, stratifying risk,
and guiding therapy.
Methods: We performed a systematic literature review to examine NP in COPD, utilising Medline, EMBASE, and
the Cochrane Library.
Results: Fifty one studies were identified. NP levels were lower in stable compared to exacerbation of COPD, and
significantly increased with concomitant left ventricular systolic dysfunction or cor pulmonale. Elevation occurred
in 16 to 60% of exacerbations and persisted in approximately one half of patients at discharge. Cardiovascular
comorbidities were associated with increased levels. Levels consistently correlated with pulmonary artery pressure and
left ventricular ejection fraction, but not pulmonary function or oxygen saturation. NP demonstrated high negative
predictive values (0.80 to 0.98) to exclude left ventricular dysfunction in both stable and exacerbation of COPD, but
relatively low positive predictive values. NP elevation predicted early adverse outcomes, but the association with long
term mortality was inconsistent.
Conclusion: NP reflect diverse aspects of the cardiopulmonary continuum which limits utility when applied in
isolation. Strategies integrating NP with additional variables, biomarkers and imaging require further investigation.
Keywords: Natriuretic peptides, Chronic obstructive pulmonary disease, Heart failure, Biomarkers
Background
COPD is the only major cause of mortality for which
death rates continue to rise. There remains a lack of
objective measures to risk-stratify patients, standardized
management of comorbidities, and therapies that
prolong life. One third of deaths in COPD relate to
cardiovascular disease, equaling or exceeding pulmonary-
related mortality [1–3]. Cardiovascular therapies are
proven to reduce morbidity and mortality, yet are
underutilized because disease is unrecognized [4]. Simple,
generalizable and cost-effective strategies are therefore
needed to identify cardiovascular disease (and particularly
heart failure) to improve outcomes in COPD.
The U.S. Food and Drug Administration and inter-
national guidelines have highlighted the need for bio-
marker development in COPD [5]. However, development
is challenging and translation into clinical practice has
been largely unsuccessful [6, 7]. Given the recognized car-
diovascular phenotypes within COPD, [8] the use of estab-
lished cardiovascular biomarkers merits exploration. The
natriuretic peptides (NP) B-type natriuretic peptide (BNP)
and N-terminal fragment (NT-proBNP) are powerful
independent predictors of death and adverse events in HF,
a broad range of cardiovascular conditions, and even in
asymptomatic individuals in the community [9]. In pri-
mary care patients at high cardiovascular risk, intensive
management of those with a raised BNP detected on sys-
tematic screening reduced the incidence of heart failure
and left ventricular dysfunction [10]. NP may therefore
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prove useful in identifying cardiovascular disease, stratify-
ing risk, and guiding therapy in COPD.
However, pulmonary disease itself, pulmonary hyper-
tension, and right ventricular strain are also associated
with NP elevation. This may undermine the utility of NP
in COPD across the spectrum of potential applications:
reduced diagnostic accuracy for HF; impaired risk strati-
fication due to transient changes or weak association
with predictors of prognosis; and by correlation with fac-
tors unresponsive to treatment. We therefore undertook
a systematic review to direct future research and provide
healthcare providers with a concise, critical, unbiased
synthesis of the expanding body of literature. The study
aims were to define the prevalence, distribution, associa-
tions, prognostic implications, and diagnostic accuracy
of peptide elevation in COPD.
Methods
Participants, outcomes and study designs
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) guidelines were followed. The
population of interest was patients with COPD receiving
natriuretic peptide testing. The outcome of interest was
NP, including: levels and proportion elevated in different
COPD populations, stratified by COPD severity (stable
disease, acute exacerbation (AECOPD), associated cor
pulmonale); thresholds used to define abnormal; cor-
relations between NP and measures of ventricular and
pulmonary function; risk associated with NP; and
accuracy of NP in diagnosing HF. All study designs
including cohort, case-control and cross-sectional
were accepted.
Search strategy and data collection
MEDLINE (from 1990), EMBASE (from 1990), and the
Cochrane Library were searched to June 2015, limited to
adult humans, without date or language restriction. Search
terms were selected by consensus and iterative database
queries. Medical Subject Headings (MeSH) and Emtree
terms were identified from keyword mapping and pub-
lished literature. COPD was identified using MeSH
(pulmonary disease, chronic obstructive; bronchitis,
chronic), Emtree (chronic obstructive lung disease; chronic
bronchitis), and keywords. NP were identified using MeSH
(natriuretic peptides), Emtree (brain natriuretic peptide),
and keywords. Terms and keywords were combined ac-
cording to the requirements of the database. The search
strategy is outlined in Appendix 1. No review protocol was
registered or published. The search identified 440 articles
in Medline and EMBASE, totalling 276 records after dupli-
cate removal (Fig. 1). Case reports, reviews and conference
abstracts were excluded. Two reviewers (NH and AK)
screened titles and abstracts (binary yes/no) with reconcili-
ation through discussion. Studies fulfilling the participant,
outcomes and study design criteria were included.
Studies involving patients with different pulmonary
diseases (as opposed to COPD) or only HF were ex-
cluded (Fig. 1). Variables of interest were decided a
priori and expanded iteratively after pilot. Excel
spreadsheets were employed as data extraction forms
and populated directly by both reviewers (NH and
AK). The following information was extracted: biblio-
graphic details, sample size and number of centers,
population, baseline characteristics and comorbidities,
pulmonary function, NP outcomes.
Study quality
In accordance with the Cochrane Collaboration and
Institute of Medicine guidance, risk of bias in observa-
tional studies was assessed in selected components with
empirical evidence and strong clinical or theoretical
grounds. A quality scale was not utilized as many have
limited development methodology, validation, arbitrary
weightings and inconsistent relationships with effect sizes.
7 bias domains were selected (selection, misclassification,
performance, detection, reporting, information and con-
founding), based on the Cochrane Collaboration Risk of
Bias Tool and Handbook and Agency for Healthcare
Research and Quality RTI Item Banks,[11–13] Judgement
of low, high or unclear risk of bias was assigned for each
domain (Appendices 2, 3 and 4).
Synthesis and analysis
The evidence is presented as a narrative synthesis given
the heterogeneous populations, diverse objectives and
outcomes examined, varying assays and thresholds, and
poorly defined confounding factors. Most importantly,
Fig. 1 Flow diagram of study selection
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the summary measures presented in many studies
(median and ranges) require transformation for meta-
analysis. We explored multiple transformation methods,
[14–16] all of which declined in accuracy with increasing
skew and underestimated the variance by up to half. We
identified 4 main groups (stable COPD/BNP, stable
COPD/NT-proBNP, exacerbation COPD/BNP, exacerba-
tion COPD/NT-proBNP). Median/IQR was more often
reported in the exacerbation and NT-proBNP studies
due to skewed distributions (Table 1). Thus transformation
for meta-analysis would introduce major error into already
large variances in a systematic manner.
Results
Fifty one studies were identified, of which 31 were pub-
lished within the preceding 5 years and 46 within the
last decade.
Study quality
Risk of bias in many domains was low with respect to
measurement of NP. Studies were typically small, pro-
spective, without interventions or exposures, cohort or
cross-sectional in design, and measured NP in all patients
using commercial validated assays. However, approxi-
mately 50% of studies exhibited selection bias, 20% lacked
objective definition of COPD, and 40% failed to report suf-
ficient information to facilitate interpretation of NP levels
(e.g. presence of HF) (Appendices 3 and 4).
Natriuretic peptides levels in patients with COPD
Stable COPD
BNP and NT-proBNP levels were normal or only mildly
elevated in stable ambulatory patients in whom HF was
excluded or infrequent (Table 1). In the seven studies
with controls, NP levels were mildly elevated (albeit sig-
nificantly) in two studies and similar to controls in the
remainder [17–23]. The three largest prospective cohort
studies in stable COPD included a higher proportion of
patients with left ventricular systolic dysfunction (LVSD)
(prevalence 11 to 15%) [24–26]. In these patients, NP
were elevated approximately 5 fold compared to those
without LVSD. Natriuretic peptides were also signifi-
cantly elevated in patients with cor pulmonale according
to various definitions [27–29].
Eight studies examined NP in stable patients stratified
by severity of COPD according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) (Appendix 5).
The 5 largest studies observed no significant differ-
ence in median or mean levels with severity, while
the 3 smallest studies reported significantly higher
NP levels in patients with more severe COPD. A
single study in 170 patients reported the proportion
of patients with elevated BNP stratified by COPD
severity [30]. NT-proBNP was elevated in GOLD
stages I to IV in 21, 21, 23 and 28% of patients, re-
spectively (p = 0.87).
Acute exacerbation COPD
Average natriuretic peptide levels were modestly higher
during exacerbations than in stable patients in three types
of comparison (Table 1): relative to reported values
from other studies in stable COPD, compared to
stable controls recruited in the same study, [31, 32]
and compared to repeated estimates in the same pa-
tient outside of an exacerbation episode [33–39]. The
time course of biomarker release relative to exacerba-
tion was rarely investigated. In 127 consecutive hospi-
talizations, NT-proBNP was elevated in 60% of
patients at admission and persisted in 28% at dis-
charge [34]. The largest study with multiple time
points found no significant decline in average NT-
proBNP sampled on days 3, 7, 14 and 35 after the oc-
currence of exacerbation [38]. Of interest, significant
elevation in NT-proBNP in that study were limited to
patients with a history of ischaemic heart disease.
Subgroups with comorbidities
In subgroups of patients with comorbidities associated
with NP release, levels were significantly increased com-
pared to those without comorbidities. These included
ischaemic heart disease, [38, 40] pulmonary emboli, [41]
arrhythmia, [32] aortic stenosis, [25] pulmonary hyper-
tension, [42] renal impairment [32, 43]. However, these
comorbidities were rarely reported or searched for sys-
tematically. For example, atrial fibrillation was only
reported in 7 studies.
Correlates and predictors of elevated natriuretic peptides
in COPD
The most consistent association was between NP and
pulmonary artery pressure, with correlation coefficients
ranging from 0.28 to 0.68, typically being around 0.5
(Table 2). In most studies with echocardiography,
NP elevation was associated with left ventricular
ejection fraction (LVEF) among patients with stable
and exacerbation of COPD, [25, 26, 32, 35, 37, 39]
even in the absence of raised pulmonary artery pres-
sures. Right ventricular function was rarely charac-
terized, and then using a variety of measures
including ejection fraction,[19] tricuspid annular
plane systolic excursion (TAPSE), [37] right ventricu-
lar diameter and hypokinesia [29, 31]. Heterogeneity
and small sample sizes limits interpretation.
The relationship between NP and FEV1 or PaO2 was
inconsistent. Similar to the evidence stratifying by
COPD severity, the smaller studies observed significant
correlations between NP and both FEV1 or PaO2. How-
ever, correlation coefficients in the two largest studies of
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208 and 80 patients were not significant (respectively
FEV1 r = 0.104 and PaO2 0.115; FEV1 r = 0.06 and PaO2
0.14). A modest significant association was observed be-
tween NP and troponin in three studies (r = 0.34 to 0.50)
[38, 44, 45].
Prevalence of natriuretic peptide elevation and thresholds
employed to define abnormal
Different strategies have been employed to define ‘abnormal’
(Table 3): ROC curve analysis to balance accuracy in pre-
dicting specific outcomes; measuring central tendency and
dispersion of normal controls (e.g. mean ± 2 SD); manufac-
turer recommendation; existing publications or investiga-
tor selection. The proportion of patients with elevated NP
according to these heterogeneous thresholds ranged from
15 to 71% in stable patients, and 16% to 60% during ex-
acerbation. Five studies employed receiver operating curve
analysis to determine optimal thresholds for detecting left
ventricular dysfunction [24, 32, 39, 43, 46]. However, only
one of these studies actually reported the prevalence of an
elevated level according to these thresholds (approximately
50% in stable patients) [24]. Moreover, identical thresholds
in different studies yielded very different frequencies of
elevation. NT-proBNP >125 pg/ml occurred in 23% and
51% of stable patients in two studies [24, 30]. Likewise,
NT-proBNP >125 pg/ml occurred in 16%, 27% and 44% of
AECOPD in three studies [37, 38, 44].
Accuracy of natriuretic peptides in detecting heart failure
in patients with COPD
Natriuretic peptides were always significantly elevated in
patients with COPD and concurrent HF or LVSD com-
pared to those without (Table 1). However, very few studies
examined predictive accuracy to identify HF or LVSD, with
just a single study in patients with stable COPD (Table 4)
[24]. Four natriuretic peptide assays produced compar-
able results in 200 stable elderly patients with a clinical
diagnosis of COPD. Each test excluded HF with reason-
able accuracy (all negative predictive values above 0.85,
with positive predictive values approximately 0.4). In
Table 3 Thresholds used to define abnormal in patients with COPD
Natriuretic peptide Threshold (pg/ml) Method of selecting threshold Proportion elevated (%)
Stable
Inoue [35] BNP 34 2 SD from mean of normal control 37
Bozkanat [28] BNP 36 investigator selection nr
Rutten [24] BNP NT–BNP 35 125 ROC curve 49 51
Watz [30] NT–BNP 125 manufacturer reference range 23
van Gestel [49] NT–BNP 500 cited review article (Jelic 2006) [87] 17
Macchia [26] NT–BNP 160 median nr
Andersen [42] NT–BNP 95 ROC for echo pulmonary hypertension 71
Anar [29] NT–BNP 125/450 (age specific) manufacturer reference range 15
Rubinsztajn [77] NT–BNP 125 manufacturer reference range 44
Ozdemirel [19] NT–BNP 84/155 (gender specific) nr nr
Exacerbation
Lee [51] BNP 88 ROC for survival 39
Gariani [47] BNP 500 guidelines 30
Abroug [46] NT–BNP 1000 and 2500 ROC rule out and in LV dysfunction nr
Sanchez-Marteles [88] NT–BNP 500 ROC for survival 53
Chang [44] NT–BNP 220 pmol/l local laboratory (also Lee 13) [37] 27
Hoiseth [45] NT–BNP 2500 based on Abroug [46] 18
Marcun [34] NT–BNP – age/sex adjusted 95 percentile 60
Ouanes [43] NT–BNP 1000/2000 (renal specific) ROC for LV dysfunction nr
Lee [37] NT–BNP 220 pmol/l local laboratory (also Chang 11) [44] 44
Wang [32] NT–BNP 935 ROC for LV dysfunction nr
Patel [38] NT–BNP 220 pmol/l based on Chang [44] 16
El Mallawany [39] NT–BNP 900 ROC for LV dysfunction nr
BNP B-type natriuretic peptide; COPD chronic obstructive pulmonary disease; LV left ventricular; NT-proBNP N-terminal proBNP; ROC receiver operator characteristic;
SD standard deviation
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three studies of patients with AECOPD, NP demon-
strated high negative predictive values (0.80 to 0.98) to
exclude left ventricular dysfunction applying thresholds ex-
ceeding the manufacturers’ guidance (Table 4) [32, 46, 47].
However, as in the stable population the positive pre-
dictive values were relatively low. Two studies also
assessed ability to detect systolic and diastolic dys-
function separately [24, 47]. The receiver operating
characteristic areas and overall accuracy in the latter
were lower though remained acceptable.
Prognostic significance of natriuretic peptides in COPD
We identified 12 studies (6 stable and 6 exacerbation of
COPD) reporting the association between NP and prog-
nosis, in which the prognostic significance of elevation
was inconsistent (Table 5). Among stable patients, the
association between NP and survival over 1 to 4 years
failed to remain significant after multivariable adjust-
ment in 3 studies [25, 35, 48]. However, NT-proBNP
>500 pg/ml predicted one year mortality in 144 patients
with predominantly mild to moderate COPD and
Table 5 Prognostic significance of natriuretic peptides in COPD
n Follow up Echo
(%)
Heart failure
details
Natriuretic peptide
threshold
Endpoints Unadjusted risk Adjusted risk
Stable
Inoue [35] 60 3 years 53 6% <50% BNP > 34.2 death
exacerbation
not significant increased not significant HR 3.8
(1.2–12.7) p = 0.02
Gale [25] 140 1 year 100 11% EF < 45% highest vs lowest
quartile
death
hospitalization
RR 3.0 (p = 0.001) not significant not
significant
Waschki
[48]
170 48 months 100 – – death HR 1.47 (1.05–2.06) 1.16 (0.97–1.39)
Andersen
[42]
117 2.8 years 100 – NT-proBNP <95 ng/L death HR 0.29 (0.09–0.97) p = 0.04 –
van Gestel
[49]
144 1 year 100 ex EF≤ 40% NT-proBNP
>500 pg/ml
death HR 4.5 (1.5–13.5) HR 7.7 (1.6–37.4)
Zeng [50] 220 22 months – 26% HF – death – 1.61 (1.27–2.06)
Exacerbation
Stolz [33] 208 2 year 75 10% LVSD per 100 pg/ml death ICU
admission
not significant 1.12 (1.03–
1.22)
not significant
1.13 (1.0–1.24)
Lee [51] 67 inpatient – – BNP >88 pg/ml death – OR 21.2 (2.5–180.4)
Chang
[44]
244 1 year 0 acute cardiac
disease ex
NT-proBNP >220
pmol/L
death 30 day
death 1 year
OR 9.0 (3.1 – 26.2) p < 0.001
1 year not significant
OR 7.5 (1.9–28.9) p = 0.004
1 year not significant
Marcun
[34]
127 6 month 100 13% EF < 55%
42% DD
age/gender
adjusted
death
hospitalization
HR 5.49 (1.25-24.00)
HR 1.34 (0.84-2.63)
HR 4.20 (1.07-14.01)
HR 1.48 (0.60-3.69)
Medina
[52]
192 1 year 0 exclude prior NT-proBNP
>588 pg/ml
death OR 3.90 (1.46-10.47)
p = 0.006
OR 3.30 (1.11–9.85)
p = 0.034
Hoiseth
[45]
99 median
1.9 years
0 21% vs 9%
tertile 3 vs 1
tertile 3 vs 1 death HR 6.9 (3.0 – 16.0)
p < 0.0001
HR 3.2 (1.3–8.1) p = 0.012
BNP B-type natriuretic peptide; COPD chronic obstructive pulmonary disease; DD diastolic dysfunction; EF left ventricular ejection fraction; HF heart failure;
HR hazard ratio; LVSD left ventricular systolic dysfunction; NT-proBNP N-terminal pro BNP; OR odds ratio; RR relative risk
Table 4 Accuracy of natriuretic peptides in predicting left ventricular systolic dysfunction
n Population %LVSD (LVEF) Threshold Left ventricular dysfunction NPV PPV
Rutten [24] 200 primary care elderly 15 (≤45%) BNP 35 pg/ml NT-BNP
125 pg/ml
panel adjudicated systolic
dysfunction
~0.95 ~0.4
Abroug [46] 148 intensive care unit 18 (<50%) NT-BNP 1000 pg/ml panel adjudicated systolic or
diastolic dysfunction
0.94 0.78
Gariani [47] 57 hospitalization retrospective 23 (<50%) BNP 500 pg/ml systolic dysfunction diastolic
dysfunction
0.88 0.80 0.47 0.41
Wang [32] 311 hospitalization 16 (<45%) NT–BNP 935 pg/ml panel adjudicated systolic or
diastolic dysfunction
0.98 0.47
BNP B-type natriuretic peptide; LVEF left ventricular ejection fraction; LVSD left ventricular systolic dysfunction; NPV negative predictive value; NT-proBNP N-terminal
proBNP; PPV positive predictive value
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preserved LVEF (>40%) undergoing major vascular sur-
gery (adjusted HR 7.7 [95% 1.6–37.4]) [49]. NT-proBNP
was also associated with all-cause mortality in a larger
cohort of 220 elderly men with COPD (adjusted HR
1.61 [1.27–2.06]), although 26% of that cohort had
documented HF [50].
In patients with AECOPD, NP independently pre-
dicted short term outcomes including intensive care unit
admission, [33] inpatient and 30 day mortality [44, 51].
Median BNP was also significantly higher in failed (in-
patient death or early re-hospitalisation) compared to
successful discharges following AECOPD hospitalization
(median (IQR) 261 (59–555) vs 49 (24–104) pg/ml) [36].
The relationship with longer term survival was less
certain. Natriuretic peptides failed to predict mortality
at 1 and 2 years in 244 and 208 consecutive patients
hospitalized or presenting to the emergency depart-
ment with exacerbation [33, 44]. However, elevated
NP were independently associated with increased mortal-
ity at 6 months, 1 year and nearly 2 years in three subse-
quent studies (respectively HR 4.2, OR 3.3 and HR 3.2)
[34, 45, 52].
Discussion
Causes of natriuretic peptide elevation in patients with
and without COPD
Myocardial stretch in either ventricle consequent to
volume or pressure overload increases NP levels [53].
Causes include heart failure with reduced and pre-
served ejection, [54, 55] right ventricular failure, [56]
pulmonary emboli, [41, 57] acute coronary syndromes,
[58, 59] valvular heart disease, [60] and arrhythmias
[61]. Advancing age and renal dysfunction are also as-
sociated with elevated NT-proBNP concentrations [62].
Many of these factors are present in stable COPD and
common non-infective precipitants of exacerbation
[32, 41, 63]. The presence and extent of each factor
varies significantly from patient to patient, and is largely
independent of COPD severity or acute right ventricular
dysfunction. Thus NP levels are higher during acute
exacerbation or chronic decompensation (cor pulmo-
nale) than stable disease, and exhibit significant variability
with skewed distributions.
By systematically searching and aggregating individual
studies, our review highlights several new and consistent
observations which suggest NP release is multifactorial
with limited direct relationship to COPD. First, NP
levels are increased even in some patients with mild
COPD without arterial hypoxaemia, severe pulmonary
hypertension or right ventricular dysfunction. Second,
levels are stable or exhibit only a minor gradient with
increasing COPD severity. Third, the magnitude of
the correlation coefficients (r) suggests only approxi-
mately 25% to 50% of the variance (r2) in NP is
attributable to any single variable. Moreover, correl-
ation between left and right ventricular function is
likewise modest (LVEF and TAPSE r = 0.46 in one
study), [37] indicating only around 20% of the vari-
ance in function of either ventricle is explained by
the function of the other.
Prognostic significance of natriuretic peptides
Individual studies have concluded that NP may be
useful in risk stratifying patients with COPD [34, 44, 49].
However, the overall literature has not previously been
summarized. The association with longer term outcomes
was inconsistent in both stable and exacerbation popu-
lations. Our findings highlight many of the challenges
in developing biomarker strategies: relatively small
sample sizes; variable performance in heterogeneous
populations; and failure to replicate findings from der-
ivation to validation cohorts [7]. At present there is
insufficient evidence to recommend routine risk strati-
fication using NP.
The more consistent prediction of early outcomes fol-
lowing exacerbations suggests that NP are more strongly
associated with acute pathologies rather than COPD it-
self [33, 44, 51]. The precise causes remains unclear, as
risk associated with many acute events improves with
time e.g. HF, PE. Nevertheless, unrecognised LVSD un-
doubtedly underpins many adverse outcomes. While NP
levels were typically modest, [44] up to one fifth of pa-
tients with AECOPD had marked elevation indicative of
probable left heart failure (although acute right ventricu-
lar strain remains possible) [45]. Moreover, the signifi-
cant unadjusted association between NT-proBNP and
mortality in one study was nulled after adjustment for
LVEF and valvular disease [25]. This hypothesis is fur-
ther supported by the high prevalence of unrecognised
heart failure in imaging and autopsy studies, [64] and
the improved outcomes associated with angiotensin con-
verting enzyme inhibitors and beta-blockers in observa-
tional COPD studies [65, 66].
Clinical application of natriuretic peptides in COPD
Natriuretic peptides exhibit lower diagnostic accuracy
for HF in COPD than in populations with acute dys-
pnoea, [67, 68] due to greater overlap of NP distribu-
tions in the respective states to be distinguished: levels
are elevated in stable and exacerbation of COPD, and
lower in stable compared to acute HF. The threshold
providing adequate sensitivity and negative predictive
value must generate sufficiently few false positives to
integrate into systems of care, be cost-effective, and im-
prove outcomes. However, the positive predictive values
in the 3 stable or exacerbation populations we identified
ranged from 0.4 to 0.47. This compares unfavourably
with a recent meta-analysis of NP in the acute care
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setting, which reported positive predictive values ranging
from 0.67 and 0.64 for BNP and NT-proBNP respect-
ively at the guideline recommended lower thresholds,
rising to 0.85 and 0.80 respectively for mid-range values
[69]. The resulting increase in false positive results will
increase demand on imaging services to confirm or
refute the diagnosis.
Directions for future research
To improve generalizability and interpretation, future
studies should use validated assays in consecutive
patients, and standardized definitions for COPD, HF and
comorbidities. Detailed cardiovascular profiles and
imaging are needed to systematically define pathologies
contributing to NP elevation. Levels should be reported
using guideline and manufacturer recommended
thresholds, for both the overall population and stratified
according to presence or absence of predictors of NP
elevation, particularly left ventricular dysfunction. Larger
studies examining cause-specific outcomes are needed.
Integrating NP with clinical variables and simple
investigations such as electrocardiograms should be
evaluated to reduce false positive results and develop
cost-effective screening strategies. The goal of improv-
ing outcomes is particularly challenged by the incon-
sistent prognostic implications of NP in COPD in
studies to date. The greatest incremental prognostic
and therapeutic value is likely in populations with
unrecognized heart failure and cardiovascular disease
amenable to treatment [34, 45, 70].
Limitations
Most of the identified studies were single centre with
limited numbers of patients and endpoints. The patient
populations, assays and cutoffs for NP, and definitions of
LVSD and HF were heterogeneous. No study systematic-
ally defined causes of NP elevation, and the proportion
amenable to therapy e.g. arrhythmia, ischaemia, LVSD,
pulmonary emboli. These comorbidities will strongly
influence every outcome examined, from symptoms to
prognosis. The causes of death in relation to NP eleva-
tion also require clarification.
Conclusions
Natriuretic peptides are often increased in patients with
COPD, reflecting three complex interwoven aspects of
the cardiopulmonary continuum: left heart systolic and
diastolic dysfunction; pulmonary vascular and right heart
remodelling; and global cardiovascular risk and comor-
bidities. The additional peptide elevation during exacer-
bations is likely a marker of both acute strain and
varying degrees of underlying cardiopulmonary dis-
ease: in some patients effectively a stress test and har-
binger of future adverse events. The balance of these
pathophysiologic abnormalities within populations is
unclear. The goal is to untangle this heterogeneity, to
identify individuals at greatest risk and facilitate tar-
geted interventions. Strategies integrating NP with
additional variables, biomarkers and imaging require
further investigation.
Appendix 1
Search strategy.
Combined Medline and Embase search strategy.
Medline and Embase
1) (exp pulmonary disease, chronic obstructive/or exp
bronchitis, chronic/) USE mesd
2) (exp *chronic obstructive lung disease/or *exp
chronic bronchitis) USE emezd
3) ((obstruct*) adj2 (pulmonary or lung* or airway* or
airflow* or bronch* or respiratory*)).ti,ab.
4) (COPD or COAD or COBD).mp.
5) or/1–4
6) (exp natriuretic peptides) USE mesd
7) (exp brain natriuretic peptide) USE emezd
8) (natriuretic adj2 peptide$ or BNP or proBNP).mp.
9) or/6–8
10) 5 and 9
11) limit 10 to humans
12) limit 11 to yr = ‘1990-Current’
13) 12 not exp newborn/not exp infant/not exp child/
not exp adolescent/
14) 13 not (case report* or review* or comment* or
editorial* or note* or conference abstract*).pt
15)..dedup 14
Appendix 2
Description of 7 risk of bias domains assessed.
Table 6 Risk of bias domains assessed
Selection Is there consecutive or random participant
sampling?
Misclassification Are key inclusion/exclusion criteria clearly stated
and defined by valid and reliable measures?
Performance Did the study vary from the protocol proposed by
the investigators, and was there appropriate ethical
approval?
Detection Is the study design prospective, retrospective, or
mixed?
Reporting Are important primary outcomes missing from the
results?
Information Were valid and reliable measures used consistently
across all study participants to assess outcomes,
exposures or interventions?
Confounding
Interpretation
Were important confounding and effect modifying
variables accounted for in the design and/or
analysis?
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Appendix 3
Risk of bias summary.
Chart demonstrating overall proportion of studies clas-
sified as low, unclear or high risk of bias within the 7
domains.
Fig. 2 Risk of bias summary
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Appendix 4
Table reporting risk of bias within the 7 domains for
each study.
Table 7 Risk of bias in individual studies
Selection Misclassify Performance Detection Reporting Information Confounding
Abroug 06 [46] Low High Low Low Low Low Low
Agoston-Coldea 14 [79] High Low Low Low Low Low Low
Akpinar 14 [41] Low Low Low Low Low Low High
Anar 12 [29] High Low High Low Low Low High
Andersen 12 [42] High Low Low Low High Low High
Anderson 13 [17] Low Low Low Low Low Low Low
Bando 99 [27] High High Low Low Low Low High
Beghe 13 [23] High Low Low Low Low Unclear High
Boschetto 13 [21] Low Low Low Low Low Unclear Low
Bozkanat 05 [28] High High Low Low Low Low Low
Cabanes 01 [72] Low Low Low Low Low Low Low
Chang 11 [44] Low Low Low Low Low Low Low
Chi 12 [84] High Low Low Low Low Low Low
El Mallawany 14 [39] High High Low Low Low Low High
Escande 14 [81] High Low Low Low Low Unclear Low
Fujii 99 [71] High Low Low Low Low Low Low
Gale 11 [25] Low Low Low Low Low Low Low
Gariani 11 [47] High High Low High High Low High
Gemici 08 [18] High Low Low Low Low Low Low
Hemlin 07 [73] High Low Low Low Low Unclear Low
Hoiseth 12 [45] Low Low Low Low Low Low Low
Hwang 07 [85] High Unclear Unclear High Unclear Unclear Unclear
Inoue 09 [35] High Low Low Low Low Low High
Kanat 07 [31] Low Low Low Low Low Low Low
Kim 10 [75] High Low Low Low Low Low High
Lee 04 [51] High Low Unclear High High Unclear High
Lee 13 [37] High Low Low Low Low Low Low
Lopez-Sanchez 13 [78] Low Low Low Low Low Unclear High
Macchia 12 [26] Low Low Low Low Low Low Low
Marcun 12 [34] Low Low Low Low Low Low High
Martins 09 [82] High High Low High High Unclear High
Murphy 09 [76] Low Low Low Low Low Low Low
Nishimura 14 [36] Low Low Low Low Low Unclear High
Ouanes 12 [43] Low Low Low Low Low Low Low
Ozdemirel 14 [19] Low Low Low Low Low Low Low
Papaioannou 10 [74] Low Low Low Low Low Low Low
Patel 12 [40] High Low Low Low High Low High
Patel 13 [38] High Low Low Low Low Low High
Rubinsztajn 13 [77] Low Low High High Low Low High
Rutten 07 [24] Low High Low Low Low Low Low
Sanchez-Marteles 09 [83] Low Low Low Low Low Low Low
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Appendix 5
Table reporting natriuretic peptide levels in 8 studies
stratified by COPD severity according to GOLD
classification.
Abbreviations
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BNP: B-type natriuretic peptide; COPD: Chronic obstructive pulmonary
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Table 7 Risk of bias in individual studies (Continued)
Sanchez-Marteles 10 [88] Low Low Low Low Unclear Low High
Stolz 08 [33] Low Low Low Low Low Low High
van Gestel 10 [49] High Low Low Low Low Low Low
Wang 11 [20] High Low Low Low Low Low Low
Wang 13 [22] High High Low Low Low Unclear Low
Wang 13 [32] Low High Low Low Low Low Low
Waschki 11 [48] Low Low Low Low Low Low Low
Watz 08 [30] High Low Low Low Low Unclear Low
Xie 13 [80] Unclear High High Low Low Low High
Zeng 13 [50] High Low Low High Low Unclear High
Table 8 Natriuretic peptide levels in patients with COPD stratified by severity
n Population Natriuretic
peptide
(pg/ml)
Median or mean peptide level according to GOLD I/II/
III/IV
Significant difference across GOLD
groups
Rutten [24] 118 stable NT-proBNP ~127/119/136/169 p = NS
Watz [30] 170 stable NT-proBNP 69/62/67/73 p = 0.78
Inoue [35] 60 stable BNP ~30/30/50/65 p < 0.01
van Gestel
[49]
144 stable NT-proBNP 212/170/352/–
Mansour [86] 57 stable BNP excluded/38/60/78 p < 0.05
Chi [84] 61 stable NT-proBNP excluded/112/151/250 p = 0.02
Nishimura [36] 190 stable BNP 18/26/22/17 p = 0.53
Rubinsztajn
[77]
81 stable NT-proBNP 114/232/155/231 p = NS
BNP brain natriuretic peptide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NT-proBNP N-terminal proBNP
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